LQDA Reports Q1

Liquidia (NASDAQ: LQDA ) released first-quarter financial results and hosted an earnings call on Monday.

Read the complete transcript below.

APIs provide real-time access to earnings call transcripts and financial data.

Visit to learn more.

The full earnings call is available at Summary Eutrepia has become a leading product in the inhaled prostacycline category, with significant prescription growth and a strong uptake among physicians, demonstrating its potential as a foundational therapy.

The company is expanding its clinical studies, including transitioning patients from other therapies to Eutrepia and exploring new indications such as PH-COPD and scleroderma-associated Raynaud's phenomenon, aiming to significantly grow the franchise value.

Laquinia Corporation has reported its third consecutive quarter of profitability, with a 44% sequential growth in net product sales, and is funding its growth initiatives through operating cash flow.

The company has achieved a half-billion-dollar annualized revenue run rate for Eutrepia in less than a year, with aspirations to reach at least $1 billion in net revenue by 2027.

Management emphasized the importance of expanding their market reach through increased sales force and driving awareness in the PH-ILD and community pulmonologist sectors.

Full Transcript Jonathan, Operator Good morning and welcome to Laquinia Corporation First Quarter 2026 Financial Results and Corporate Update conference call.

My name is Jonathan and I will be your operator today.

All participants are currently in a listen-only mode.

Following the presentation, we will conduct a question and answer session.

Instructions for joining the queue will be provided at that time.

Please note that today's call is being recorded.

And now I'd like to turn the call over to Jason Adair, Laquinia's Chief Business Officer.

You may proceed.

Jason Adair, Chief Business Officer Thank you and good morning everyone.

It's my pleasure to welcome you to our first quarter 2026 financial results and Corporate Update call.

Joining me today are Dr.

Roger Jeffs, Chief Executive Officer, Michael Caseta, Chief Operating Officer and Chief Financial Officer, Dr.

Rajeev Sagar, Chief Medical Officer, Scott Moonmaw, Chief Commercial Officer, and Rufti Sundar, our General Counsel.

Before we begin, please note that today's discussion will include forward-looking statements including statements regarding future results, product performance, and ongoing clinical or commercial activities.

These statements are subject to risks and uncertainties that may cause actual results to differ materially.

For further information, please refer to our filings with the SEC which are available on our website.

Please also note that our earnings release and our commentary include non-GAAP financial measures.

Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures can be found in our earnings press release.

With that, I'll turn the call over to Roger.

Roger Jeffs, Chief Executive Officer Thanks Jason and good morning everyone.

We're delighted to share our business results with you today.

We'll keep our prepared remarks somewhat brief this morning as we'd like to allow as much time for questions as we can.

Having said that, I'd like to share some bigger picture thoughts regarding the state of the business and allow the Q&A to serve as time to delve into the specifics.

Three full quarters into the commercial launch of Eutrepia, I would summarize the state of our business with three main points.

The first is that in the third full quarter on the market, Eutrepia is now leading the growth of the inhaled prostacycline category.

Eutrepia is well on its way to becoming the anchored inhaled therapy for patients with PAH and PH ID.

As of April 30th, we have received approximately 4,500 unique patient prescriptions and started approximately 3,750 patients on therapy since launch, and approximately 980 physicians have prescribed Eutrepia since launch.